EXHIBIT 3

Stephen P. Swinton (106398)
LATHAM & WATKINS LLP
600 West Broadway
Suite 800
San Diego, CA 92101-3375
Telephone: (619) 236-1234
Facsimile: (619) 696-7419
Email: steve.swinton@lw.com

Nina M. Gussack
Kenneth J. King
Allan A. Thoen
PEPPER HAMILTON LLP
3000 Two Logan Square
Eighteenth & Arch Streets
Philadelphia, PA 19103-2799
Telephone: (215) 981-4000
Facsimile: (215) 981-4750
E-mail: gussackn@pepperlaw.com
E-mail: kingk@pepperlaw.com
E-mail: thoena@pepperlaw.com
Attorneys for Defendant
Eli Lilly and Company, a corporation

UNITED STATES DISTRICT COURT
SOUTHERN DISTRICT OF CALIFORNIA

IN RE INCRETIN-BASED THERAPIES PRODUCTS LIABILITY LITIGATION As to All Related and Member Cases	MDL No. 2452 Magistrate: Mitchell D. Dembin Judge: Anthony J. Battaglia **DEFENDANT ELI LILLY AND COMPANY'S OBJECTIONS AND RESPONSES TO PLAINTIFFS' GENERAL CAUSATION REQUESTS TO PRODUCE**

PROPOUNDING PARTY: Plaintiff

RESPONDING PARTY: Defendant Eli Lilly and Company

SET NUMBER: General Causation

Pursuant to Rule 34 of the Federal Rules of Civil Procedure, defendant Eli Lilly and Company ("Lilly") hereby responds and objects to the General Causation Requests to Produce propounded by the Plaintiffs' Steering Committee as follows:

PREFACE

1. Lilly co-promoted Byetta with Amylin Pharmaceuticals, LLC ("Amylin") pursuant to a collaboration agreement in effect from September 2002 until November 2011. Lilly's co-promotion of Byetta ended in November 2011, and Lilly has concluded its exenatide-related activities and transitioned all exenatide related activities and responsibilities to Amylin, with minor exceptions not material here in certain other countries pending formal transfer of the Market Authorization in those countries. Unless otherwise stated, Lilly's responses to these requests to produce are within the date scope of January 1, 2002 through March 31, 2013.

2. Amylin and Lilly have to date produced several million DOCUMENTS to members of the Plaintiffs' Steering Committee ("PSC"). In December 2012, Amylin and Lilly produced 4.5 million pages of DOCUMENTS covering the period before December 28, 2009, including the Byetta IND/NDA, the ADVERSE EVENT reporting database, and custodial DOCUMENTS from the following safety, regulatory, medical, and marketing custodians involved with Byetta:

Amylin

- Diane Beck - Director, Regulatory and Global Safety Operations
- Gary Bloomgren - Senior Director, R&D
- Tom Carpenter - VP, R&D Operations
- Staci Ellis - Director, Regulatory Affairs
- Mark Fineman - Senior Director, R&D Strategic Relations
- Orville Kolterman - Senior VP, R&D
- Dana Lee - Director, Pharmacovigilance
- David Maggs - VP, R&D Strategic Relations,
- Oleg Martynov - Director of Global Safety
- David Parkes - Senior Director, InVivo Pharmacology
- Ruth Patterson - Director of Medical Writing
- Lisa Porter - VP, R&D ExenatideOne
- Denis Roy - Senior Director, Global Pre-Clinical Lead
- Catherine Schnabel - Associate Director, Medical Affairs
- Kika Teudt - Manager, Regulatory Affairs
- Cheryl Watton - Executive Director, Regulatory Affairs and Global Safety
- Dawn Viveash - VP, Regulatory Affairs and Global Safety

Lilly

- Pamela Anderson - Medical Fellow, U.S. Medical Endocrinology
- Dan Braun - Medical Fellow, Global Patient Safety
- Kathryn Broderick - Advisor, Global Regulatory Affairs U.S.
- Jeffrey Ferguson - Medical Fellow, Global Patient Safety
- Drew Fine - Product Brand Director
- John Holcombe - Medical Fellow
- James Malone - Senior Medical Director
- Michael Cobas Meyer - Senior Director, Global Patient Safety
- Rebecca Noel - Research Scientist, Epidemiology
- Donald Therasse - Vice President of Global Patient Safety
- Douglas Wilson - Senior Director of Brand Marketing

On September 27, 2013, Amylin and Lilly provided members of the PSC an updated production consisting of more than five hundred thousand pages of additional DOCUMENTS covering the period from late-2009 to November 2012, including custodial DOCUMENTS from six safety, regulatory and medical custodians involved with Byetta.

3. Lilly objects to Plaintiffs' "Definitions and Instructions" to the extent they purport to impose any obligation on Lilly beyond the obligations imposed by Rule

33 of the Federal Rules of Civil Procedure or to alter the commonly understood meaning of words or phrases.

4. All references to BYETTA within Lilly's responses shall refer to the twice daily injectable form of exenatide, Byetta®, that was first approved by the FDA on April 28, 2005.

5. All references to "Exenatide" (also known as "exendin-4") shall refer to the 39-amino acid synthetic peptide and is the active ingredient in BYETTA.

6. Lilly objects to each request to the extent it seeks information protected by the attorney-client privilege and/or attorney work product doctrine and will withhold such information.

7. Lilly objects to each request to the extent it seeks information protected by HIPAA or other patient confidentiality laws or privileges.

8. It is Lilly's understanding that Plaintiffs' revised requests for production replace their prior requests, that Plaintiffs have withdrawn the prior requests, and that Defendants' responses to the previously served requests are no longer usable in this litigation. If Plaintiffs' dispute this understanding, then Plaintiffs have exceeded the number of permitted requests that they are entitled to serve under the CMO entered on February 23, 2014, and Lilly objects on that basis.

OBJECTIONS AND RESPONSES

REQUEST NO. 1:

The DOCUMENTS identified in YOUR answers to Plaintiffs' General Causation Interrogatories to Defendant Eli Lilly and Company.

RESPONSE:

Lilly has produced or is producing the documents specifically identified, by bates number or other identifier, as responsive in its answers to Plaintiffs' General Causation Interrogatories.

REQUEST NO. 2:

The IND/NDA and any SNDAs for BYETTA in native electronic searchable format as maintained by YOU.

RESPONSE:

Lilly objects to this request as misdirected to it and refers Plaintiffs to Amylin, the regulatory approval holder for Byetta, for the materials sought by this request. By way of further response, Lilly states that the Byetta IND/NDA, covering the period before December 28, 2009, was previously produced to Plaintiffs at BY00000001-435050, and refers Plaintiffs to Amylin regarding supplementation of this production.

REQUEST NO. 3:

All other correspondence, data and other DOCUMENTS that YOU provided to or received from the FDA related to the safety of BYETTA with respect to pancreatitis and/or pancreatic cancer, which are not part of the IND/NDA or any SNDAs for BYETTA.

RESPONSE:

Lilly objects to this request as misdirected to it and refers Plaintiffs to Amylin, the regulatory approval holder for Byetta, for the materials sought by this request. Lilly objects to providing information also in the possession, custody or control of Amylin which may more reasonably be obtained from it. By way of further response, Lilly notes that communications with the FDA, through December 28, 2009, were previously produced to Plaintiffs (*see* BY00390802-BY00403814 and BY00416354-BY00418067), and refers Plaintiffs to Amylin regarding supplementation of this production.

REQUEST NO. 4:

Corporate organization charts that identify the persons with supervisory responsibility over scientific research into the safety of BYETTA and

those working at their direction; the persons responsible for determining whether BYETTA CAUSES and/or is capable of CAUSING pancreatic cancer and those working at their direction; the persons in charge of compiling and reporting pancreatitis and/or pancreatic cancer ADVERSE EVENTS for BYETTA and those working at their direction; and the persons in charge of maintaining the source DOCUMENTS for pancreatitis and/or pancreatic cancer ADVERSE EVENTS for BYETTA and those working at their direction.

RESPONSE:

Lilly has previously produced organizational charts responsive to this request and is supplementing its prior production with additional charts, the bates numbers of which will be identified under separate cover. Lilly objects to this request as not seeking information relevant to whether Byetta is capable of causing pancreatic cancer, to the extent it purports to require the creation of charts not already existing, and to the extent it seeks production of charts encompassing more than the individuals whose custodial files are most likely to contain documents within the scope of general causation discovery. Lilly further objects to this request as ambiguous and interprets it as seeking charts of Lilly's Global Patient Safety organization.

REQUEST NO. 5:

A complete list of all BYETTA preclinical, nonclinical and/or animal studies performed, completed, designed, planned and/or contemplated, identifying them by name, number or any other designation YOU use to identify them.

RESPONSE:

Lilly objects to this request as improper under Rule 34 in that it purports to require creation of a document not already existing in the ordinary course and as duplicative of Plaintiffs' General Causation Interrogatory No. 2.

Lilly refers Plaintiffs to its objections and answer to General Causation Interrogatory No. 2, which are incorporated by reference as if set forth fully here.

REQUEST NO. 6:

For each BYETTA preclinical, nonclinical and/or animal study performed, completed, designed, planned and/or contemplated, produce the following:

a. The protocols; data; researcher and/or laboratory technician notebooks, notes, logs, bench notes, books, computer files and emails; results; reports; and pancreatic specimens (e.g. histology slides, tissue samples, etc.) for that study;

b. The database(s) where the above information can be located; and

c. If an independent investigator, contract research organization, or other third party was involved in the study, produce all DOCUMENTS relating to the work performed, including but not limited to contracts and communications between YOU and said independent investigator, contract research organization, or other third party.

RESPONSE:

Lilly refers Plaintiffs to Amylin for information related to preclinical, nonclinical or animal (collectively, "nonclinical") studies for Byetta. See Lilly's answer to Plaintiffs' General Causation Interrogatory No. 2. Lilly further objects to this request as overbroad and unduly burdensome to the extent it seeks documents regarding nonclinical studies not relevant to general causation and to the extent it seeks documents or materials regarding studies (such as slides, samples, lab notebooks, etc.) beyond those contained in the study report and its attachments. The burden and expense of collecting and producing all such requested materials for every study, regardless of relevance, is unreasonable. Lilly also refers Plaintiffs

to its production of custodial files, which Plaintiffs are equally able to search as Lilly for emails and other documents discussing these studies.

REQUEST NO. 7:

The standard operating procedures and/or policy and procedures manuals for BYETTA preclinical, nonclinical and animal studies.

RESPONSE:

Lilly refers Plaintiffs to Amylin for information related to preclinical, nonclinical or animal (collectively, "nonclinical") studies for Byetta. See Lilly's answer to Plaintiffs' General Causation Interrogatory No. 2. Lilly further objects to this request as overbroad and unduly burdensome to the extent it seeks documents regarding nonclinical studies not relevant to general causation and to the extent it seeks documents or materials regarding studies (such as slides, samples, lab notebooks, etc.) beyond those contained in the study report and its attachments. The burden and expense of collecting and producing all such requested materials for every study, regardless of relevance, is unreasonable.

REQUEST NO. 8:

Every DOCUMENT that addresses the significance of any preclinical, nonclinical and/or animal study in relation to whether BYETTA CAUSES and/or is capable of CAUSING pancreatic cancer.

RESPONSE:

Lilly objects to this request as overbroad, ambiguous, and not reasonably calculated to lead to discovery of evidence competent to prove or disprove general causation. As drafted, this request encompasses every document containing second- or third-hand opinions by any individuals regardless of their expertise or knowledge. Lilly objects to this request to the extent it seeks documents outside Lilly's possession, custody, or control or that are publicly and

equally available to Plaintiffs. Lilly also objects to this request to the extent it seeks documents protected by the attorney-client privilege or work product doctrine.

Lilly is preparing for production, in accordance with the schedule set by the Court, custodial files collected using search terms agreed upon with Plaintiffs for certain custodians involved in analysis of the safety of Byetta, including Richard Byrd, Ph.D., Jeff Ferguson, M.D., Daniel Braun, M.D., Richard Bump, M.D., Michael Cobas Meyer, M.D., and Steven Knowles, M.D. By way of further response, Plaintiffs also have available numerous analyses contained in Byetta's IND and NDA, and in Periodic Safety Update Reports and Risk Management Plans produced to date, and which are being supplemented by Amylin.

REQUEST NO. 9:

The memoranda, reports and other similar DOCUMENTS that describe the nature and intended purpose of any preclinical, nonclinical and/or animal studies involving BYETTA that are not yet started or completed and, to the extent such DOCUMENTS exist, the protocols; data; researcher and/or laboratory technician notebooks, notes, logs, bench notes, books, computer files and emails; results; reports; and pancreatic specimens (e.g. histology slides, tissue samples, etc.) for each such preclinical, nonclinical and/or animal study.

RESPONSE:

Lilly objects to this request as misdirected to it and refers Plaintiffs to Amylin for the documents sought by this request. Lilly's collaboration agreement with Amylin regarding Byetta terminated in November 2011, and Lilly has concluded and transitioned all exenatide related activities and responsibilities to Amylin, with minor exceptions not material here in certain countries pending formal transfer of the Market Authorization. Lilly further objects to this request as not reasonably calculated to lead to discovery of evidence relevant to general

causation to the extent it seeks information about ongoing or future studies, which have yet to yield data.

REQUEST NO. 10:

A complete list of all BYETTA human studies performed, completed, designed, planned and/or contemplated, identifying them by name, number or any other designation YOU use to identify them.

RESPONSE:

Lilly objects to this request as improper under Rule 34 in that it purports to require creation of a document not already existing in the ordinary course and as duplicative of Plaintiffs' General Causation Interrogatory No. 2. Lilly refers Plaintiffs to its objections and answer to General Causation Interrogatory No. 2, which are incorporated by reference as if set forth fully here.

REQUEST NO. 11:

For each BYETTA human study performed, completed, designed, planned and/or contemplated, produce the following:

a. The protocols; data; researcher and/or laboratory technician notebooks, notes, logs, bench notes, books, computer files and emails; results; reports; and pancreatic specimens (e.g. histology slides, tissue samples, etc.) for that study;

b. The database(s) where the above information can be located;

c. All documentation and/or communication regarding sponsorship of the study; and

d. If an independent investigator, contract research organization, or other third party was involved in the study, produce all DOCUMENTS relating to the work performed, including but not limited to contracts and communications

between YOU and said independent investigator, contract research organization, or other third party.

RESPONSE:

In response to this request, Lilly refers Plaintiffs to the table of studies provided in its answer to General Causation Interrogatory Nos. 2 and 6, and to the materials associated with each study as identified in that table, which have already been produced to Plaintiffs or are being produced by Lilly and/or Amylin. Lilly also refers Plaintiffs to its production of custodial files, which Plaintiffs are equally able to search as Lilly for emails and other documents discussing these studies. Lilly's collaboration agreement with Amylin terminated in November 2011, and Lilly has concluded its exenatide-related activities and transitioned all exenatide related activities and responsibilities to Amylin, with minor exceptions not material here in certain countries pending formal transfer of the Market Authorization. Lilly, therefore, objects to this request as unduly burdensome and duplicative to the extent it seeks production from Lilly of study materials that may also be obtained from Amylin. Lilly objects to this request as not reasonably calculated to lead to discovery of evidence relevant to general causation to the extent it seeks information about ongoing or future studies, which have yet to yield data. Lilly also objects to this request as overbroad and unduly burdensome to the extent it seeks documents for every study beyond the materials identified in the table provided in response to General Causation Interrogatory Nos. 2 and 6. The burden and expense of collecting and producing all additional requested materials for every study, regardless of relevance, is unnecessary and unreasonable. If after reviewing the study reports Plaintiffs identify specific additional materials regarding specific studies, Lilly will meet and confer with Plaintiffs regarding the additional materials Plaintiffs seek.

REQUEST NO. 12:

The standard operating procedures and/or policy and procedures manuals for BYETTA human studies.

RESPONSE:

Lilly is producing copies of the standard operating procedures from its Medical Quality System listed in Appendix 2 hereto, covering the period from September 2002 through March 31, 2013.

REQUEST NO. 13:

Every DOCUMENT that records, analyzes or discusses information about each person YOU are aware of who was a participant in a BYETTA human study and was diagnosed with pancreatitis and/or pancreatic cancer either while still participating in the study or after withdrawing or otherwise being removed from the study.

RESPONSE:

Lilly refers Plaintiffs to its objections and answers to General Causation Interrogatory Nos. 21 and 22 and to the documents identified in its answers to those interrogatories. Lilly further responds that it is preparing for production, in accordance with the schedule set by the Court, custodial files collected using search terms agreed upon with Plaintiffs for certain custodians involved in the analysis of the safety of Byetta, including Richard Byrd, Ph.D., Jeff Ferguson, M.D., Daniel Braun, M.D., Richard Bump, M.D., Michael Cobas Meyer, M.D., and Steven Knowles, M.D., in addition to custodial files already produced. Plaintiffs are equally able as Lilly to search these custodial files for documents sought by this request. Lilly objects to this request to the extent that it includes material protected by the attorney-client privilege and/or attorney work product doctrine.

REQUEST NO. 14:

Every DOCUMENT that addresses the significance of any human study in relation to whether BYETTA CAUSES and/or is capable of CAUSING pancreatic cancer.

RESPONSE:

Lilly objects to this request as ambiguous, overbroad, and not reasonably calculated to lead to the discovery of evidence competent to prove or disprove general causation. As drafted, this request encompasses every document containing second- or third-hand opinions by any individuals regardless of their expertise or knowledge. Lilly objects to this request to the extent it seeks documents outside Lilly's possession, custody or control or that are publicly and equally available to Plaintiffs. Lilly also objects to this request to the extent it seeks documents protected by the attorney-client privilege or work product doctrine.

Lilly is preparing for production, in accordance with the schedule set by the Court, custodial files collected using search terms agreed upon with Plaintiffs for certain custodians involved in analysis of the safety of Byetta, including Jeff Ferguson, M.D., Daniel Braun, M.D., Richard Bump, M.D., Michael Cobas Meyer, M.D., Steven Knowles, M.D., and James Malone, M.D. By way of further response, Plaintiffs also have available numerous analyses contained in the IND and NDA, and in Periodic Safety Update Reports and Risk Management Plans produced to date, and which are being supplemented by Amylin.

REQUEST NO. 15:

The memoranda, reports and other similar DOCUMENTS that describe the nature and intended purpose of any human studies involving BYETTA that are not yet started or completed and, to the extent such DOCUMENTS exist, the study protocols; data; researcher and/or laboratory technician notebooks, notes,

logs, bench notes, books, computer files and emails; results; reports; and pancreatic specimens (e.g. histology slides, tissue samples, etc.) for each such human study.

RESPONSE:

Lilly objects to this request as misdirected to it and refers Plaintiffs to Amylin for the documents sought by this request. Lilly's collaboration agreement with Amylin regarding Byetta terminated in November 2011, and Lilly has concluded its exenatide-related activities and transitioned all exenatide related activities and responsibilities to Amylin, with minor exceptions not material here in certain countries pending formal transfer of the Market Authorization. Lilly further objects to this request as not reasonably calculated to lead to discovery of evidence relevant to general causation to the extent it seeks information about ongoing or future studies, which have yet to yield data.

REQUEST NO. 16:

A complete list of all BYETTA observational studies (including, without limitation, claims database studies, cohort studies and other epidemiological studies) performed, completed, designed, planned and/or contemplated, identifying them by name, number or any other designation YOU use to identify them.

RESPONSE:

Lilly objects to this request as improper under Rule 34 in that it purports to require creation of a document not already existing in the ordinary course and as duplicative of Plaintiffs' General Causation Interrogatory No. 2. Lilly refers Plaintiffs to its objections and answer to General Causation Interrogatory No. 2, which are incorporated by reference as if set forth fully here.

REQUEST NO. 17:

For each BYETTA observational study (including, without limitation, claims database studies, cohort studies and other epidemiological studies) performed, completed, designed, planned and/or contemplated, produce the following:

a. The protocols; data; researcher and/or laboratory technician notebooks, notes, logs, bench notes, books, computer files and emails; results; and reports for that study;

b. The database(s) where the above information can be located; and

c. If an independent investigator, contract research organization, or other third party was involved in the study, produce all DOCUMENTS relating to the work performed, including but not limited to contracts and communications between YOU and said independent investigator, contract research organization, or other third party.

RESPONSE:

Lilly objects to the phrase "observational studies" as used in this request as ambiguous and interprets this request as referring to epidemiological studies not involving human subjects. In response to this request, Lilly refers Plaintiffs to the table of studies provided in its answers to General Causation Interrogatory Nos. 2 and 9 and to the materials associated with each study as identified in that table, which have already been produced to Plaintiffs or are being produced by Lilly and/or Amylin. Lilly also refers Plaintiffs to its production of custodial files, which Plaintiffs are equally able to search as Lilly for emails and other documents discussing these studies. Lilly is preparing for production, in accordance with the schedule set by the Court, custodial files, collected using search terms agreed upon with Plaintiffs, for Rebecca Noel and Stephen Motsko,

both epidemiologists involved in preparation and analysis of epidemiological studies regarding Byetta.

Lilly's collaboration agreement with Amylin terminated in November 2011, and Lilly has concluded its exenatide-related activities and transitioned all exenatide related activities and responsibilities to Amylin, with minor exceptions not material here in certain countries pending formal transfer of the Market Authorization. Lilly therefore objects to this request as unduly burdensome and duplicative to the extent it seeks production from Lilly of study materials which may also be obtained from Amylin. Lilly objects to this request as not reasonably calculated to lead to discovery of evidence relevant to general causation to the extent it seeks information about ongoing or future studies, which have yet to yield data. Lilly also objects to this request as overbroad and unduly burdensome to the extent it seeks documents for every study beyond the materials identified in the table provided in response to General Causation Interrogatory Nos. 2 and 9. The burden and expense of collecting and producing all additional requested materials for every study, regardless of relevance, is unnecessary and unreasonable. If after reviewing the study reports Plaintiffs identify specific additional materials regarding specific studies, Lilly will meet and confer with Plaintiffs regarding the additional materials Plaintiffs seek.

REQUEST NO. 18:

The standard operating procedures and/or policy and procedures manuals for BYETTA observational studies (including, without limitation, claims database studies, cohort studies and other epidemiological studies).

RESPONSE:

Lilly refers Plaintiffs to the individual study reports of epidemiological studies for the methodology followed by the study. By way of further response, Lilly refers Plaintiffs to the Safety Quality System procedures it has produced and

is producing (see Appendix 1 hereto) for procedures related to post-marketing surveillance and signal evaluation.

REQUEST NO. 19:

Every DOCUMENT that addresses the significance of any observational studies (including, without limitation, claims database studies, cohort studies and other epidemiological studies) in relation to whether BYETTA CAUSES and/or is capable of CAUSING pancreatic cancer.

RESPONSE:

Lilly objects to this request as ambiguous, overbroad and not reasonably calculated to lead to discovery of evidence competent to prove or disprove general causation. As drafted, this request encompasses every document containing any opinions by any individuals regardless of their expertise or knowledge. Lilly objects to this request to the extent it seeks documents outside Lilly's possession, custody or control or that are publicly and equally available to Plaintiffs. Lilly also objects to this request to the extent it seeks documents protected by the attorney-client privilege or work product doctrine.

Lilly is preparing for production, in accordance with the schedule set by the Court, custodial files collected using search terms agreed upon with Plaintiffs for certain custodians involved in analysis of the safety of Byetta, including epidemiologists, Stephen Motsko, Ph.D. and Rebecca Noel, Ph.D., and physicians, Jeff Ferguson, M.D., Daniel Braun, M.D., Richard Bump, M.D., Michael Cobas Meyer, M.D., Steven Knowles, M.D., and James Malone, M.D. By way of further response, Plaintiffs also have available numerous analyses contained in the IND and NDA, and in Periodic Safety Update Reports and Risk Management Plans produced to date, and which are being supplemented by Amylin.

REQUEST NO. 20:

The memoranda, reports and other similar DOCUMENTS that describe the nature and intended purpose of any observational studies (including, without limitation, claims database studies, cohort studies and other epidemiological studies) involving BYETTA that are not yet started or completed and, to the extent such DOCUMENTS exist, the study protocols; data; researcher and/or laboratory technician notebooks, notes, logs, bench notes, books, computer files and emails; results; and reports for each such study.

RESPONSE:

Lilly objects to this request as misdirected to it and refers Plaintiffs to Amylin for the documents sought by this request. Lilly's collaboration agreement with Amylin regarding Byetta terminated in November 2011, and Lilly has concluded its exenatide-related activities and transitioned all exenatide related activities and responsibilities to Amylin, with minor exceptions not material here in certain countries pending formal transfer of the Market Authorization. Lilly further objects to this request as not reasonably calculated to lead to discovery of evidence relevant to general causation to the extent it seeks information about ongoing or future studies, which have yet to yield data.

REQUEST NO. 21:

The standard operating procedures and/or policy and procedures manuals for BYETTA studies undertaken to determine, in whole or in part, whether BYETTA CAUSES and/or is capable of CAUSING pancreatic cancer.

RESPONSE:

Lilly refers Plaintiffs to the Safety Quality System and Medical Quality System procedures that it has produced and is producing, which are listed in Appendices 1 and 2 hereto.

REQUEST NO. 22:

The study protocols; data; researcher and/or laboratory technician notebooks, notes, logs, bench notes, books, computer files and emails; results; and reports that were provided to the FDA for each study, test, investigation, evaluation and/or assessment undertaken by YOU for the purpose of determining, in whole or in part, whether BYETTA CAUSES and/or is capable of CAUSING pancreatic cancer.

RESPONSE:

Lilly objects to this request as misdirected to it and refers Plaintiffs to Amylin, the regulatory approval holder for Byetta in the United States, for the materials sought by this request as Lilly does not have current information as to which documents have been provided to the FDA. Lilly's collaboration agreement with Amylin regarding Byetta terminated in November 2011. Lilly has concluded its exenatide-related activities and transitioned all exenatide related activities and responsibilities to Amylin, with minor exceptions not material here in certain other countries pending formal transfer of the Market Authorization in those countries. Lilly objects to providing information also in the possession, custody or control of Amylin which may more reasonably be obtained from it. By way of further response, Lilly refers Plaintiffs to its responses to Request Nos. 2 and 3 above.

REQUEST NO. 23:

The study protocols; data; researcher and/or laboratory technician notebooks, notes, logs, bench notes, books, computer files and emails; results; and reports that were not provided to the FDA for each study, test, investigation, evaluation and/or assessment undertaken by YOU for the purpose of determining, in whole or in part, whether BYETTA CAUSES and/or is capable of CAUSING pancreatic cancer.

RESPONSE:

Lilly objects to this request as misdirected to it and refers Plaintiffs to Amylin, the regulatory approval holder for Byetta in the United States, for the materials sought by this request as Lilly does not have current information as to which documents have been provided to the FDA. Lilly's collaboration agreement with Amylin regarding Byetta terminated in November 2011. Lilly has concluded its exenatide-related activities and transitioned all exenatide related activities and responsibilities to Amylin, with minor exceptions not material here in certain other countries pending formal transfer of the Market Authorization in those countries. Lilly objects to providing information also in the possession, custody or control of Amylin which may more reasonably be obtained from it. By way of further response, Lilly refers Plaintiffs to its responses to Request Nos. 2 and 3 above.

REQUEST NO. 24:

The study protocols; data; researcher and/or laboratory technician notebooks, notes, logs, bench notes, books, computer files and emails; results; and reports that were provided to the EMA for each study, test, investigation, evaluation and/or assessment undertaken by YOU for the purpose of determining, in whole or in part, whether BYETTA CAUSES and/or is capable of CAUSING pancreatic cancer.

RESPONSE:

Lilly objects to this request as misdirected to it and refers Plaintiffs to Amylin, the regulatory approval holder for Byetta in the European Union, for the materials sought by this request as Lilly does not have current information as to which documents have been provided to the EMA. Lilly's collaboration agreement with Amylin regarding Byetta terminated in November 2011, and EMA Market Authorization for Byetta was transferred from Lilly to Bristol-Myers Squibb and AstraZeneca on March 6, 2013. Lilly has concluded its exenatide-related activities and transitioned all exenatide related activities and responsibilities to Amylin, with

minor exceptions not material here in certain other countries pending formal transfer of the Market Authorization in those countries. Lilly objects to providing information also in the possession, custody or control of Amylin which may more reasonably be obtained from it. By way of further response, Lilly refers Plaintiffs to its responses to Request Nos. 2 and 3 above. Lilly objects to discovery related to foreign regulatory issues as not relevant to this litigation, which involves Byetta labeling and use in the United States. However, in light of the unique circumstance in this litigation of EMA and FDA having jointly conducted and published an assessment of pancreatic cancer, Lilly will produce its EMA regulatory files for Byetta and Bydureon for the period in which it was the Market Authorization Holder in the European Union. Lilly maintains its position that submissions and communications with foreign regulatory agencies generally are irrelevant in U.S. product liability litigation.

REQUEST NO. 25:

The study protocols; data; researcher and/or laboratory technician notebooks, notes, logs, bench notes, books, computer files and emails; results; and reports that were not provided to the EMA for each study, test, investigation, evaluation and/or assessment undertaken by YOU for the purpose of determining, in whole or in part, whether BYETTA CAUSES and/or is capable of CAUSING pancreatic cancer.

RESPONSE:

Lilly objects to this request as misdirected to it and refers Plaintiffs to Amylin, the regulatory approval holder for Byetta in the European Union, for the materials sought by this request as Lilly does not have current information as to which documents have been provided to the EMA. Lilly's collaboration agreement with Amylin regarding Byetta terminated in November 2011, and EMA Market Authorization for Byetta transferred from Lilly to Bristol-Myers Squibb and

AstraZeneca on March 6, 2013. Lilly has concluded its exenatide-related activities and transitioned all exenatide related activities and responsibilities to Amylin, with minor exceptions not material here in certain other countries pending formal transfer of the Market Authorization in those countries. Lilly objects to providing information also in the possession, custody or control of Amylin which may more reasonably be obtained from it. Lilly objects to discovery of foreign regulatory issues as not relevant to this litigation, which involves Byetta labeling and use in the United States. However, in light of the unique circumstance in this litigation of EMA and FDA having jointly conducted and published an assessment of pancreatic cancer, Lilly will produce its EMA regulatory files for Byetta and Bydureon for the period in which it was the Market Authorization Holder in the European Union. Lilly maintains its position that submissions and communications with foreign regulatory agencies generally are irrelevant in U.S. product liability litigation.

REQUEST NO. 26:

Every DOCUMENT that addresses the significance of any study, test, investigation, evaluation and/or assessment undertaken by YOU for the purpose of determining, in whole or in part, whether BYETTA CAUSES and/or is capable of CAUSING pancreatic cancer, in relation to whether BYETTA CAUSES and/or is capable of CAUSING pancreatic cancer.

RESPONSE:

This request is duplicative of Request Nos. 8, 14 and 19 above, and Lilly refers Plaintiffs to its objections and responses to those requests, which are incorporated as if set forth fully here.

REQUEST NO. 27:

The memoranda, reports and other similar DOCUMENTS that describe the nature and intended purpose of any study, test, investigation,

evaluation and/or assessment undertaken by YOU for the purpose of determining, in whole or in part, whether BYETTA CAUSES and/or is capable of CAUSING pancreatic cancer, that is not yet started or completed and, to the extent such DOCUMENTS exist, the study protocols; data; researcher and/or laboratory technician notebooks, notes, logs, bench notes, books, computer files and emails; results; and reports for each such study, test, investigation, evaluation and/or assessment.

RESPONSE:

This request is duplicative of Request Nos. 9, 15 and 20, above, and Lilly refers Plaintiffs to its objections and responses to those requests, which are incorporated as if set forth fully here.

REQUEST NO. 28:

The standard operating procedures and/or policy and procedures manuals for all other studies YOU are aware of that bear, in whole or in part, on whether BYETTA CAUSES and/or is capable of CAUSING pancreatic cancer (whether such study, test, investigation, evaluation and/or assessment involves BYETTA, another GLP-1 receptor or DPP-4 inhibitor, any other drug, or no drug).

RESPONSE:

This request is duplicative of Request Nos. 7, 12, 18 and 21, above, and Lilly refers Plaintiffs to its objections and responses to those requests, which are incorporated as if set forth fully here. Lilly also objects to this request to the extent it seeks documents related to products other than Byetta, which is the product at issue in Plaintiffs' claims against Lilly. Discovery directed to Lilly regarding other compounds in the GLP-1 or DPP-4 classes is overbroad, unduly burdensome, and not reasonably calculated to lead to admissible evidence.

REQUEST NO. 29:

Every DOCUMENT that addresses the significance of any other study, test, investigation, evaluation and/or assessment YOU are aware of that bears, in whole or in part, on whether BYETTA CAUSES and/or is capable of CAUSING pancreatic cancer (whether such study, test, investigation, evaluation and/or assessment involves BYETTA, another GLP-1 receptor or DPP-4 inhibitor, any other drug, or no drug), in relation to whether BYETTA CAUSES pancreatic cancer.

RESPONSE:

This request is duplicative of Request Nos. 8, 14, 19, and 26 above, and Lilly refers Plaintiffs to its objections and responses to those requests, which are incorporated as if set forth fully here. Lilly also objects to this request to the extent it seeks documents related to products other than Byetta, which is the product at issue in Plaintiffs' claims against Lilly. Discovery directed to Lilly regarding other compounds in the GLP-1 or DPP-4 classes is overbroad, unduly burdensome, and not reasonably calculated to lead to admissible evidence.

REQUEST NO. 30:

The memoranda, reports and other similar DOCUMENTS that describe the nature and intended purpose of any other study, test, investigation, evaluation and/or assessment YOU are aware of that bears, in whole or in part, on whether BYETTA CAUSES and/or is capable of CAUSING pancreatic cancer (whether such study, test, investigation, evaluation and/or assessment involves BYETTA, another GLP-1 receptor or DPP-4 inhibitor, any other drug, or no drug) that is not yet started or completed and, to the extent such DOCUMENTS exist, the study protocols; data; researcher and/or laboratory technician notebooks, notes, logs, bench notes, books, computer files and emails; results; reports; and pancreatic

specimens (e.g., histology slides, tissue samples, etc.) for each such other study, test, investigation, evaluation and/or assessment.

RESPONSE:

This request is duplicative of Request Nos. 9, 15, 20 and 27 above, and Lilly refers Plaintiffs to its objections and responses to those requests, which are incorporated as if set forth fully here. Lilly also objects to this request to the extent it seeks documents related to products other than Byetta, which is the product at issue in Plaintiffs' claims against Lilly. Discovery directed to Lilly regarding other compounds in the GLP-1 or DPP-4 classes is overbroad, unduly burdensome, and not reasonably calculated to lead to admissible evidence.

REQUEST NO. 31:

The study protocols; data; researcher and/or laboratory technician notebooks, notes, logs, bench notes, books, computer files and emails; results; reports; and pancreatic specimens (e.g., histology slides, tissue samples, etc.) that were provided to the FDA for any other study, test, investigation, evaluation and/or assessment YOU are aware of that bears, in whole or in part, on whether BYETTA CAUSES and/or is capable of CAUSING pancreatic cancer (whether such study, test, investigation, evaluation and/or assessment involves BYETTA, another GLP-1 receptor or DPP-4 inhibitor, any other drug, or no drug).

RESPONSE:

Lilly objects to this request as misdirected to it and refers Plaintiffs to Amylin, the regulatory approval holder for Byetta in the United States, for the materials sought by this request as Lilly does not have current information as to which documents have been provided to the FDA. Lilly's collaboration agreement with Amylin regarding Byetta terminated in November 2011. Lilly has concluded its exenatide-related activities and transitioned all exenatide related activities and responsibilities to Amylin, with minor exceptions not material here in certain other

countries pending formal transfer of the Market Authorization in those countries. Lilly objects to providing information also in the possession, custody or control of Amylin which may more reasonably be obtained from it. Lilly also objects to this request to the extent it seeks documents related to products other than Byetta, which is the product at issue in Plaintiffs' claims against Lilly. Discovery directed to Lilly regarding other compounds in the GLP-1 or DPP-4 classes is overbroad, unduly burdensome, and not reasonably calculated to lead to admissible evidence. By way of further response, Lilly refers Plaintiffs to its responses to Request Nos. 2 and 3 above.

REQUEST NO. 32:

The study protocols; data; researcher and/or laboratory technician notebooks, notes, logs, bench notes, books, computer files and emails; results; reports; and pancreatic specimens (e.g., histology slides, tissue samples, etc.) that were not provided to the FDA for any other study, test, investigation, evaluation and/or assessment YOU are aware of that bears, in whole or in part, on whether BYETTA CAUSES and/or is capable of CAUSING pancreatic cancer (whether such study, test, investigation, evaluation and/or assessment involves BYETTA, another GLP-1 receptor or DPP-4 inhibitor, any other drug, or no drug).

RESPONSE:

Lilly objects to this request as misdirected to it and refers Plaintiffs to Amylin, the regulatory approval holder for Byetta in the United States, for the materials sought by this request as Lilly does not have current information as to which documents have been provided to the FDA. Lilly's collaboration agreement with Amylin regarding Byetta terminated in November 2011. Lilly has concluded its exenatide-related activities and transitioned all exenatide related activities and responsibilities to Amylin, with minor exceptions not material here in certain other countries pending formal transfer of the Market Authorization in those countries.

Lilly objects to providing information also in the possession, custody or control of Amylin which may more reasonably be obtained from it. Lilly also objects to this request to the extent it seeks documents related to products other than Byetta, which is the product at issue in Plaintiffs' claims against Lilly. Discovery directed to Lilly regarding other compounds in the GLP-1 or DPP-4 classes is overbroad, unduly burdensome, and not reasonably calculated to lead to admissible evidence. By way of further response, Lilly refers Plaintiffs to its responses to Request Nos. 2 and 3 above.

REQUEST NO. 33:

The study protocols; data; researcher and/or laboratory technician notebooks, notes, logs, bench notes, books, computer files and emails; results; reports; and pancreatic specimens (e.g., histology slides, tissue samples, etc.) that were provided to the EMA for any other study, test, investigation, evaluation and/or assessment YOU are aware of that bears, in whole or in part, on whether BYETTA CAUSES and/or is capable of CAUSING pancreatic cancer (whether such study, test, investigation, evaluation and/or assessment involves BYETTA, another GLP-1 receptor or DPP-4 inhibitor, any other drug, or no drug).

RESPONSE:

Lilly objects to this request as misdirected to it and refers Plaintiffs to Amylin, the regulatory approval holder for Byetta in the European Union, for the materials sought by this request as Lilly does not have current information as to which documents have been provided to the EMA. Lilly's collaboration agreement with Amylin regarding Byetta terminated in November 2011, and EMA Market Authorization for Byetta transferred from Lilly to Bristol-Myers Squibb and AstraZeneca on March 6, 2013. Lilly has concluded its exenatide-related activities and transitioned all exenatide related activities and responsibilities to Amylin, with minor exceptions not material here in certain other countries pending formal

transfer of the Market Authorization in those countries. Lilly objects to providing information also in the possession, custody or control of Amylin which may more reasonably be obtained from it. Lilly objects to this request to the extent it seeks documents related to products other than Byetta, which is the product at issue in Plaintiffs' claims against Lilly. Discovery directed to Lilly regarding other compounds in the GLP-1 or DPP-4 classes is overbroad, unduly burdensome, and not reasonably calculated to lead to admissible evidence. Lilly also objects to discovery of foreign regulatory issues as not relevant to this litigation, which involves Byetta labeling and use in the United States. However, in light of the unique circumstance in this litigation of EMA and FDA having jointly conducted and published an assessment of pancreatic cancer, Lilly will produce its EMA regulatory files for Byetta and Bydureon for the period in which it was the Market Authorization Holder in the European Union. Lilly maintains its position that submissions and communications with foreign regulatory agencies generally are irrelevant in U.S. product liability litigation.

REQUEST NO. 34:

The study protocols; data; researcher and/or laboratory technician notebooks, notes, logs, bench notes, books, computer files and emails; results; reports; and pancreatic specimens (e.g., histology slides, tissue samples, etc.) that were not provided to the EMA for any other study, test, investigation, evaluation and/or assessment YOU are aware of that bears, in whole or in part, on whether BYETTA CAUSES and/or is capable of CAUSING pancreatic cancer (whether such study, test, investigation, evaluation and/or assessment involves BYETTA, another GLP-1 receptor or DPP-4 inhibitor, any other drug, or no drug).

RESPONSE:

Lilly objects to this request as misdirected to it and refers Plaintiffs to Amylin, the regulatory approval holder for Byetta in the European Union, for the

materials sought by this request as Lilly does not have current information as to which documents have been provided to the EMA. Lilly's collaboration agreement with Amylin regarding Byetta terminated in November 2011, and EMA Market Authorization for Byetta transferred from Lilly to Bristol-Myers Squibb and AstraZeneca on March 6, 2013. Lilly has concluded its exenatide-related activities and transitioned all exenatide related activities and responsibilities to Amylin, with minor exceptions not material here in certain other countries pending formal transfer of the Market Authorization in those countries. Lilly objects to providing information also in the possession, custody or control of Amylin which may more reasonably be obtained from it. By way of further response, Lilly refers Plaintiffs to its responses to Request Nos. 2 and 3 above. Lilly objects to discovery of foreign regulatory issues as not relevant to this litigation, which involves Byetta labeling and use in the United States. However, in light of the unique circumstance in this litigation of EMA and FDA having jointly conducted and published an assessment of pancreatic cancer, Lilly will produce its EMA regulatory files for Byetta and Bydureon for the period in which it was the Market Authorization Holder in the European Union. Lilly maintains its position that submissions and communications with foreign regulatory agencies generally are irrelevant in U.S. product liability litigation.

REQUEST NO. 35:

All emails, letters, reports, memoranda and other written communications YOU have sent to or received from any governmental agency (including, without limitation, the FDA and EMA) or any other entity or person regarding whether BYETTA or any other GLP-1 agonist or DPP-4 inhibitor CAUSES and/or is capable of CAUSING pancreatitis and/or pancreatic cancer.

RESPONSE:

With respect to communications with the FDA and EMA, this request is duplicative of Request Nos. 2, 3, 22, 24, 31 and 33 above, and Lilly refers Plaintiffs to its objections and responses to those requests. To the extent this request seeks "all" correspondence with "any other entity or person," Lilly objects to this request as overbroad, unduly burdensome, and not reasonably calculated to lead to discovery of competent evidence regarding general causation. The relevance of evidence to general causation does not depend on whether it was communicated to some "other entity or person." Lilly also objects this request to the extent it seeks documents related to products other than Byetta, which is the product at issue in Plaintiffs' claims against Lilly. Discovery directed to Lilly regarding other compounds in the GLP-1 or DPP-4 classes is overbroad, unduly burdensome and not reasonably calculated to lead to admissible evidence. Lilly further objects to this request to the extent it includes material protected by the attorney-client privilege and/or attorney work product doctrine. Lilly also objects to this interrogatory as overbroad to the extent it seeks information regarding pancreatitis.

REQUEST NO. 36:

If any of YOUR employees, officers, directors, agents, contractors, key opinion leaders, members of speakers' bureaus, advisory board members, or scientific advisors corresponded with or supplied information or data to the European Medicines Agency (EMA) about or in connection with any assessments of whether BYETTA or any other GLP-1 agonist or DPP-4 inhibitor CAUSES and/or is capable of CAUSING pancreatic cancer (including, without limitation, as reflected in the EMA's 2013 "Assessment report for GLP-1 based therapies" and its 2014 "Pancreatic Safety of Incretin-Based Drugs - FDA and EMA Assessment"),

produce the correspondence, information or data provided to the EMA, and any correspondence or other DOCUMENTS YOU received from the EMA in response.

RESPONSE:

In light of the unique circumstance in this litigation of EMA and FDA having jointly conducted and published an assessment of pancreatic cancer, Lilly will produce its EMA regulatory files for Byetta and Bydureon for the period in which it was the Market Authorization Holder in the European Union. Lilly's collaboration agreement with Amylin regarding Byetta terminated in November 2011, and EMA Market Authorization for Byetta transferred from Lilly to Bristol-Myers Squibb and AstraZeneca on March 6, 2013. Lilly maintains its position that submissions and communications with foreign regulatory agencies generally are irrelevant in U.S. product liability litigation and objects to any other discovery of foreign regulatory issues as not relevant to this litigation, which involves Byetta labeling and use in the United States.

Lilly also objects to this request as overbroad, unduly burdensome, and not reasonably calculated to lead to admissible evidence in that it seeks documents related to products other than Byetta, which is the only product at issue in Plaintiffs' claims against Lilly. Discovery directed to Lilly regarding other compounds in the GLP-1 or DPP-4 classes is overbroad, unduly burdensome, and not reasonably calculated to lead to admissible evidence. Lilly also objects to this interrogatory as overbroad to the extent it seeks information regarding pancreatitis. Lilly further objects to this request as overbroad, unreasonably burdensome, and exceeding the scope of Rule 34 to the extent it seeks production from Lilly of communications by third parties such as "contractors, key opinion leaders, members of speakers' bureaus, advisory board members, or scientific advisors."

REQUEST NO. 37:

If any of YOUR employees, officers, directors, agents, contractors, key opinion leaders, members of speakers' bureaus, advisory board members, or scientific advisors corresponded with or supplied information or data to the FDA about or in connection with any assessments of whether BYETTA or any other GLP-1 agonist or DPP-4 inhibitor CAUSES and/or is capable of CAUSING pancreatic cancer (including, without limitation, as reflected in the FDA's 2014 "Pancreatic Safety of Incretin-Based Drugs - FDA and EMA Assessment"), produce the correspondence, information or data, and any correspondence or other DOCUMENTS YOU received from the FDA in response.

RESPONSE:

Lilly objects to this request as misdirected to it and refers Plaintiffs to Amylin, the regulatory approval holder for Byetta in the United States, for the materials sought by this request. By way of further response, Lilly refers Plaintiffs to its responses to Request Nos. 2 and 3 above.

Lilly also objects to this request as overbroad, unduly burdensome, and not reasonably calculated to lead to admissible evidence in that it seeks documents related to products other than Byetta, which is the only product at issue in Plaintiffs' claims against Lilly. Discovery directed to Lilly regarding other compounds in the GLP-1 or DPP-4 classes is overbroad, unduly burdensome, and not reasonably calculated to lead to admissible evidence. Lilly also objects to this interrogatory as overbroad to the extent it seeks information regarding pancreatitis. Lilly further objects to this request as overbroad, unreasonably burdensome, and exceeding the scope of Rule 34 to the extent it seeks production from Lilly of communications by third parties such as "contractors, key opinion leaders, members of speakers' bureaus, advisory board members, or scientific advisors."

REQUEST NO. 38:

The standard operating procedures and/or policy and procedures manuals for the handling of pancreatitis and pancreatic cancer ADVERSE EVENTS and REPORTABLE EVENTS pertaining to BYETTA.

RESPONSE:

Lilly refers Plaintiffs to the procedures of its Global Patient Safety department it has produced and is producing, which are listed in Appendix 1 hereto and which cover the period prior to March 2013, when Lilly's role in adverse event processing terminated.

REQUEST NO. 39:

Produce in electronic format complete copies of all databases used to track, trend, or record information regarding pancreatitis and pancreatic cancer ADVERSE EVENTS that YOU associated with BYETTA. To the extent that YOUR databases incorporate the following information for pancreatitis and pancreatic cancer ADVERSE EVENTS for BYETTA, this request includes:

a. All DOCUMENTS and information in YOUR possession regarding each ADVERSE EVENT;

b. Whether the ADVERSE EVENT was in the form of a MedWatch Report, communication from a medical provider or consumer, an ADVERSE EVENT REPORT ("AER") or some other form;

c. All attempts YOU made to communicate with anyone to gather further information regarding each ADVERSE EVENT;

d. All communications YOU made or received, including the substance of the communications, the identities of any persons YOU communicated with internally, and the identities of any persons YOU communicated with externally regarding each ADVERSE EVENT;

e. The nature and results of any investigations YOU conducted to determine the CAUSE of each ADVERSE EVENT, and/or the basis of any decisions not to investigate;

f. Any experts and/or consultants whom YOU contacted regarding any ADVERSE EVENT;

g. YOUR deliberations and decision-making processes used to determine whether each ADVERSE EVENT was or was not a REPORTABLE EVENT;

h. Any action YOU took as a result of each ADVERSE EVENT;

i. YOUR analysis and conclusions as to the nature, severity and frequency of each ADVERSE EVENT;

j. All ADVERSE EVENT report forms, including supplemental reports and related information, that were submitted to the FDA for each ADVERSE EVENT;

k. The current status or final disposition of each ADVERSE EVENT; and

l. Any reporting rates analysis and/or trending analysis done regarding each ADVERSE EVENT.

To the extent that YOUR databases do not incorporate some or all of the information referenced above in subparts a-l, produce the equivalent information by reference to the business records in which YOU store it.

RESPONSE:

Lilly previously produced to Plaintiffs adverse drug reaction reports from the Lilly Safety System in an electronic database format through December 28, 2009. *See* LILLY00250453. Lilly is also preparing for production, in accordance with the schedule established by the Court, custodial files collected using search terms agreed upon with Plaintiffs for certain custodians involved in analysis of the adverse drug reaction reports, including Jennifer Brookfield,

Pharm.D., Jeff Ferguson, M.D., Daniel Braun, M.D., Richard Bump, M.D., Michael Cobas Meyer, M.D., and Steven Knowles, M.D. In addition, Lilly refers Plaintiffs to the previously produced Periodic Safety Update Reports (PSURs) and Periodic Adverse Drug Experience Reports (PADERs) for Byetta, including Section 3 of the PADERs and Section 6 of the PSURs. Each PSUR also contains appendices, including "Initial and Follow Up Cases and Summary Tabulation of Initial Adverse Drug Events for HCP Not Related and Nonmedically Confirmed Cases" and "Line Listing of Initial and Follow Up Cases and Summary Tabulation of Initial Adverse Drug Reactions for HCP Related Cases." Previously produced PSURs are located at BY00354544 -BY00354720, BY00361407 - BY00361697, BY00364677 - BY00365031, BY00368455 - BY00368736, BY00372712 - BY00377032, BY00378123 -BY00382063, BY00383891 - BY00383989, BY00387699 - BY00387818, BY00412579 - BY00415581, BY00435059 - BY00437894, BY00437954 -BY00440386, BY00440399 - BY00442435, BY00442447 - BY00444523, BY00444535 - BY00446418, BY00446430 - BY00449028.

Lilly's collaboration agreement with Amylin regarding Byetta terminated in November 2011, and Lilly has concluded its exenatide-related activities and transitioned all exenatide related activities and responsibilities to Amylin, with minor exceptions not material here in certain countries pending formal transfer of the Market Authorization. Lilly objects to this request as unduly burdensome and cumulative to the extent it seeks production from Lilly of documents other than those described in the preceding paragraph and refers Plaintiffs to Amylin for further production in response to this request. Lilly further objects to this request as overbroad, unduly burdensome, and not reasonably calculated to lead to discovery of admissible evidence to the extent it seeks information about adverse events unrelated to the conditions at issue in this litigation, including pancreatitis. Lilly objects to this request to the extent it seeks confidential patient or reporter information, including to the extent it seeks source

materials, which require redactions. The burden of preparing and redacting source materials for all adverse drug reactions is unreasonable relative to the minimal relevance and cumulative information contained in such documents. Lilly also objects to this request to the extent it seeks information protected by the attorney-client privilege or work product doctrine.

REQUEST NO. 40:

The complete file that YOU established and maintain in response to each individual pancreatitis and pancreatic cancer ADVERSE EVENT for BYETTA (commonly known as "source files," ADVERSE EVENT report files, backup files, or files containing source documentation related to ADVERSE EVENTS). This request seeks the production of all DOCUMENTS and information contained or discussed in the source files for each ADVERSE EVENT, which should contain most or all of the DOCUMENTS and information described in the preceding request in subparts a-1.

RESPONSE:

This request is duplicative of Request No. 39 above, including subpart 39(a). Lilly refers Plaintiffs to its objections and response to Request No. 39, which are incorporated as if set forth fully here.

REQUEST NO. 41:

To the extent not already produced in response to the preceding requests, produce all DOCUMENTS for each pancreatitis and pancreatic cancer REPORTABLE EVENT for BYETTA, including the following:

a. All DOCUMENTS and information in YOUR possession regarding each REPORTABLE EVENT;

b. Whether the REPORTABLE EVENT was in the form of a MedWatch Report, communication from a medical provider or consumer, an ADVERSE EVENT REPORT ("AER") or some other form;

c. All attempts YOU made to communicate with anyone to gather further information regarding each REPORTABLE EVENT;

d. All communications YOU made or received, including the substance of the communications, the identities of any persons YOU communicated with internally, and the identities of any persons YOU communicated with externally regarding each REPORTABLE EVENT;

e. The nature and results of any investigations YOU conducted to determine the CAUSE of each REPORTABLE EVENT, and/or the basis of any decisions not to investigate;

f. Any experts and/or consultants whom YOU contacted regarding any REPORTABLE EVENT;

g. YOUR deliberations and decision-making processes used to determine whether each underlying ADVERSE EVENT was or was not a REPORTABLE EVENT;

h. Any action YOU took as a result of each REPORTABLE EVENT;

i. YOUR analysis and conclusions as to the nature, severity and frequency of each REPORTABLE EVENT;

j. All REPORTABLE EVENT report forms, including supplemental reports and related information, that were submitted to the FDA for each REPORTABLE EVENT;

k. The current status or final disposition of each REPORTABLE EVENT; and

l. Any reporting rates analysis and/or trending analysis done regarding each REPORTABLE EVENT.

RESPONSE:

This request is duplicative of Request Nos. 39 and 40 above. Lilly refers Plaintiffs to its objections and response to Request No. 39, which are incorporated as if set forth fully here.

REQUEST NO. 42:

All DOCUMENTS that state or discuss any request by the FDA that YOU conduct post-market surveillance of BYETTA with respect to pancreatitis and pancreatic cancer. Include in your response any correspondence, plans, reports, or other DOCUMENTS submitted by YOU to the FDA in response.

RESPONSE:

Lilly refers Plaintiffs to the IND and NDA for Byetta® submitted to the FDA, previously produced to Plaintiffs through December 28, 2009. *See* BY00000001 - BY00449028. Lilly further directs Plaintiffs to the previously produced Byetta Periodic Safety Update Reports at BY00354544 -BY00354720, BY00361407 - BY00361697, BY00364677 - BY00365031, BY00368455 - BY00368736, BY00372712 - BY00377032, BY00378123 - BY00382063, BY00383891 - BY00383989, BY00387699 - BY00387818, BY00412579 - BY00415581, LILLY01449666 - LILLY01451800, BY00437954 - BY00440386, BY00440399 - BY00442435, BY00442447 - BY00444523, BY00444535 - BY00446418, and BY00446430 - BY00449028. Lilly further responds that documents potentially responsive to this request are also contained in custodial files of Lilly employees produced to Plaintiffs. Lilly is preparing for supplemental production, in accordance with the schedule established by the Court, custodial files collected using search terms agreed upon with Plaintiffs for certain custodians involved in analysis of the adverse drug reaction reports, including Jennifer Brookfield, Pharm.D., Jeff Ferguson, M.D., Daniel Braun, M.D., Richard Bump, M.D., Michael Cobas Meyer, M.D., and Steven Knowles, M.D.

Lilly's collaboration agreement with Amylin regarding Byetta terminated in November 2011, and Lilly has concluded its exenatide-related activities and transitioned all exenatide related activities and responsibilities to Amylin, with minor exceptions not material here in certain countries pending formal transfer of the Market Authorization. Lilly objects to this request as unduly burdensome and cumulative to the extent it seeks production from Lilly of documents other than those described in the preceding paragraph and refers Plaintiffs to Amylin for further production in response to this request. Lilly also objects to this interrogatory as overbroad to the extent it seeks information regarding pancreatitis. Lilly further objects to this request as not reasonably calculated to lead to discovery of admissible evidence to the extent it seeks documents unrelated to the conditions at issue in this litigation. Lilly also objects to this request to the extent it seeks confidential patient or reporter information and to the extent it seeks information protected by the attorney-client privilege or work product doctrine.

REQUEST NO. 43:

All charts, graphs, schematics, reports, memoranda and other similar DOCUMENTS analyzing, summarizing and/or reporting on pancreatitis and/or pancreatic cancer ADVERSE EVENTS for BYETTA, including all such DOCUMENTS that compare BYETTA to any other therapeutic agent(s) for the treatment of type 2 diabetes. To the extent that such DOCUMENTS were prepared in color, they should also be produced in color.

RESPONSE:

Lilly directs Plaintiffs to the previously produced Byetta Periodic Safety Update Reports at BY00354544 -BY00354720, BY00361407 - BY00361697, BY00364677 - BY00365031, BY00368455 - BY00368736, BY00372712 - BY00377032, BY00378123 - BY00382063, BY00383891 -

BY00383989, BY00387699 - BY00387818, BY00412579 - BY00415581, LILLY01449666 - LILLY01451800, BY00437954 - BY00440386, BY00440399 - BY00442435, BY00442447 - BY00444523, BY00444535 - BY00446418, and BY00446430 - BY00449028. Lilly further responds that documents potentially responsive to this request are also contained in custodial files of Lilly employees produced to Plaintiffs. Lilly is preparing for supplemental production, in accordance with the schedule established by the Court, custodial files collected using search terms agreed upon with Plaintiffs for certain custodians involved in analysis of the adverse drug reaction reports, including Jennifer Brookfield, Pharm.D., Jeff Ferguson, M.D., Daniel Braun, M.D., Richard Bump, M.D., Michael Cobas Meyer, M.D., and Steven Knowles, M.D.

Lilly's collaboration agreement with Amylin regarding Byetta terminated in November 2011, and Lilly has concluded its exenatide-related activities and transitioned all exenatide related activities and responsibilities to Amylin, with minor exceptions not material here in certain countries pending formal transfer of the Market Authorization. Lilly objects to this request as unduly burdensome and cumulative to the extent it seeks production from Lilly of documents other than those described in the preceding paragraph and refers Plaintiffs to Amylin for further production in response to this request. Lilly also objects to this interrogatory as overbroad to the extent it seeks information regarding pancreatitis. Lilly also objects to this request to the extent it includes material protected by the attorney-client privilege and/or attorney work product doctrine.

REQUEST NO. 44:

All reports, memoranda and other DOCUMENTS that list and/or explain the criteria YOU use to determine whether any particular pancreatitis and/or pancreatic cancer ADVERSE EVENT is related to the patient's use of BYETTA.

RESPONSE:

Lilly refers Plaintiffs to the procedures of its Global Patient Safety department it has produced and is producing, which are listed in Appendix 1 hereto and which cover the period prior to March 2013, when Lilly's role in adverse event processing terminated. Lilly further responds that documents potentially responsive to this request are also contained in custodial files of Lilly employees produced to Plaintiffs. Lilly is preparing for supplemental production, in accordance with the schedule established by the Court, custodial files collected using search terms agreed upon with Plaintiffs for certain custodians involved in analysis of the adverse drug reaction reports, including Jennifer Brookfield, Pharm.D., Jeff Ferguson, M.D., Daniel Braun, M.D., Richard Bump, M.D., Michael Cobas Meyer, M.D., and Steven Knowles, M.D.

Lilly objects to this request to the extent it includes material protected by the attorney-client privilege and/or attorney work product doctrine. Lilly also objects to this interrogatory as overbroad to the extent it seeks information regarding pancreatitis.

REQUEST NO. 45:

All medical and scientific literature that YOUR company has identified that relates to the association between BYETTA or any other GLP-1 agonist or DPP-4 inhibitor and pancreatitis and/or pancreatic cancer.

RESPONSE:

Lilly objects to this request, which purports to require an evaluation of whether of publicly available literature "relates" to general causation, as unduly burdensome and not reasonably calculated to lead to discovery of any evidence relevant to general causation that is not already equally available to Plaintiffs and their experts. Lilly also objects to this request to the extent it includes material protected by the attorney-client privilege and/or attorney work product doctrine.

Lilly refers Plaintiffs to Section 11 of the PBRERs, Section 13 of the PSURs, and Sections 1.13.1.4 and 1.13.2..2 of each Annual Report for references to medical literature relevant to Byetta. Lilly further responds that documents potentially responsive to this request are contained in custodial files of Lilly employees produced to Plaintiffs. Lilly is preparing for supplemental production, in accordance with the schedule established by the Court, custodial files collected using search terms agreed upon with Plaintiffs for certain custodians involved in analysis of the adverse drug reaction reports, including Jennifer Brookfield, Pharm.D., Jeff Ferguson, M.D., Daniel Braun, M.D., Richard Bump, M.D., Michael Cobas Meyer, M.D, and Steven Knowles, M.D.

Lilly also objects to this request to the extent it seeks documents related to products other than Byetta, which is the product at issue in Plaintiffs' claims against Lilly. Discovery directed to Lilly regarding other compounds in the GLP-1 or DPP-4 classes is overbroad, unduly burdensome, and not reasonably calculated to lead to admissible evidence. Lilly also objects to this interrogatory as overbroad to the extent it seeks information regarding pancreatitis.

REQUEST NO. 46:

All reports, analyses, presentations, memoranda and other DOCUMENTS YOU are aware of that address, in whole or in part, whether BYETTA or any other GLP-1 agonist or DPP-4 inhibitor CAUSES and/or is capable of CAUSING pancreatitis and/or pancreatic cancer.

RESPONSE:

Lilly refers Plaintiffs to the IND and NDA for Byetta® submitted to the FDA, previously produced to Plaintiffs through December 28, 2009. *See* BY00000001 - BY00449028. Lilly also directs Plaintiffs to the previously produced Byetta Periodic Safety Update Reports at BY00354544 -BY00354720, BY00361407 - BY00361697, BY00364677 - BY00365031, BY00368455 -

BY00368736, BY00372712 - BY00377032, BY00378123 - BY00382063, BY00383891 - BY00383989, BY00387699 - BY00387818, BY00412579 - BY00415581, LILLY01449666 - LILLY01451800, BY00437954 - BY00440386, BY00440399 - BY00442435, BY00442447 - BY00444523, BY00444535 - BY00446418, and BY00446430 - BY00449028. Lilly further responds that documents responsive to this request are also contained in custodial files of Lilly employees produced to Plaintiffs. Lilly is preparing for supplemental production, in accordance with the schedule established by the Court, custodial files collected using search terms agreed upon with Plaintiffs for certain custodians involved in analysis of the safety of Byetta, including Jeff Ferguson, M.D., Daniel Braun, M.D., Richard Bump, M.D., Michael Cobas Meyer, M.D., Steven Knowles, M.D., Richard Byrd, Ph.D., and James Malone, M.D.

Lilly's collaboration agreement with Amylin regarding Byetta terminated in November 2011, and Lilly has concluded its exenatide-related activities and transitioned all exenatide related activities and responsibilities to Amylin, with minor exceptions not material here in certain countries pending formal transfer of the Market Authorization. Lilly objects to this request as unduly burdensome and cumulative to the extent it seeks production from Lilly of documents other than those described in the preceding paragraph and refers Plaintiffs to Amylin for further production in response to this request. Lilly also objects to this request to the extent it includes material protected by the attorney-client privilege and/or attorney work product doctrine. Lilly also objects to this interrogatory as overbroad to the extent it seeks information regarding pancreatitis. Lilly also objects to this request to the extent it seeks documents related to products other than Byetta, which is the product at issue in Plaintiffs' claims against Lilly. Discovery directed to Lilly regarding other compounds in the GLP-1 or DPP-4 classes is overbroad, unduly burdensome, and not reasonably calculated to lead to admissible evidence. Lilly further objects to this request to the extent it seeks

documents not within Lilly's possession, custody, or control or which are publicly and equally available to Plaintiffs.

REQUEST NO. 47:

To the extent not already produced in response to the preceding requests, all published and unpublished medical and scientific literature, reports, analyses, presentations, memoranda and other DOCUMENTS YOU are aware of that address whether BYETTA or any other GLP-1 agonist or DPP-4 inhibitor CAUSES the proliferation of abnormal or dysfunctional beta cells; the proliferation of abnormal or dysfunctional alpha cells; the expansion of pancreatic ductal glands in rats; the formation of dysplastic lesions and chronic pancreatitis in mice; increases in the weight and/or size of the exocrine pancreas; the inhibition of apoptosis of pancreatic ductal cells; and the inhibition of apoptosis of pancreatic islet cells.

RESPONSE:

This request is duplicative of Request Nos. 45 and 46 above, and Lilly refers Plaintiffs to its objections and response to those requests, which are incorporated as if set forth fully here.

REQUEST NO. 48:

To the extent not already produced in response to the preceding requests, all published and unpublished medical and scientific literature, reports, analyses, presentations, memoranda and other DOCUMENTS YOU are aware of that address the mechanism of action of BYETTA or any other GLP-1 agonist or DPP-4 inhibitor.

RESPONSE:

This request is duplicative of Request Nos. 45 and 46 above, and Lilly refers Plaintiffs to its objections and response to those requests, which are incorporated as if set forth fully here.

REQUEST NO. 49:

To the extent not already produced in response to the preceding requests, all published and unpublished medical and scientific literature, reports, analyses, presentations, memoranda and other DOCUMENTS YOU are aware of that address the effect that BYETTA or any other GLP-1 agonist or DPP-4 inhibitor has on the pancreas.

RESPONSE:

This request is duplicative of Request Nos. 45 and 46 above, and Lilly refers Plaintiffs to its objections and response to those requests, which are incorporated as if set forth fully here. Lilly further objects to this request as overbroad and not reasonably calculated to lead to discovery of evidence relevant to general causation of pancreatic cancer, to the extent it seeks documents pertaining broadly to any "effect … on the pancreas" regardless of whether relevant to pancreatic cancer. Lilly also objects to this request to the extent it seeks documents related to products other than Byetta, which is the product at issue in Plaintiffs' claims against Lilly. Discovery directed to Lilly regarding other compounds in the GLP-1 or DPP-4 classes is overbroad, unduly burdensome, and not reasonably calculated to lead to admissible evidence.

REQUEST NO. 50:

All reports, memoranda and other DOCUMENTS that list and/or explain the criteria YOU use to determine whether BYETTA or any other GLP-1

agonist or DPP-4 inhibitor CAUSES and/or is capable of CAUSING pancreatitis and/or pancreatic cancer.

RESPONSE:

This request is duplicative of Request No. 44 above, and Lilly refers Plaintiffs to its objections and response to that request, which are incorporated as if set forth fully here. Lilly also objects to this request to the extent it seeks documents related to products other than Byetta, which is the product at issue in Plaintiffs' claims against Lilly. Discovery directed to Lilly regarding other compounds in the GLP-1 or DPP-4 classes is overbroad, unduly burdensome, and not reasonably calculated to lead to admissible evidence. Lilly also objects to this interrogatory as overbroad to the extent it seeks information regarding pancreatitis.

REQUEST NO. 51:

All medical and/or scientific literature that YOU have reported to the FDA or any other regulatory authorities that relates to the association between BYETTA and pancreatitis and/or pancreatic cancer, including, but not limited to, all PSURs, PADERS/PAERS, and independent submissions.

RESPONSE:

Lilly objects to this request as misdirected to it and refers Plaintiffs to Amylin, the regulatory approval holder for Byetta in the United States and the European Union, for the materials sought by this request as Lilly does not have current information as to which documents have been provided to the FDA or EMA. Lilly's collaboration agreement with Amylin regarding Byetta terminated in November 2011. Lilly has concluded its exenatide-related activities and transitioned all exenatide related activities and responsibilities to Amylin, with minor exceptions not material here in certain other countries pending formal transfer of the Market Authorization in those countries. Lilly objects to providing information also in the possession, custody or control of Amylin which may more

reasonably be obtained from it. By way of further response, Lilly refers Plaintiffs to its responses to Request Nos. 2 and 3 above.

Lilly objects to discovery of foreign regulatory issues as not relevant to this litigation, which involves Byetta labeling and use in the United States. However, in light of the unique circumstance in this litigation of EMA and FDA having jointly conducted and published an assessment of pancreatic cancer, Lilly will produce its EMA regulatory files for Byetta and Bydureon for the period in which it was the Market Authorization Holder in the European Union. Lilly maintains its position that submissions and communications with foreign regulatory agencies generally are irrelevant in U.S. product liability litigation. Lilly also objects to this interrogatory as overbroad to the extent it seeks information regarding pancreatitis.

REQUEST NO. 52:

To the extent not already produced in response to the preceding requests, produce all communications, analyses, expert analyses, safety board analyses, independent analyses, and/or meta-analyses that pertain to, reference, or in any way discuss any of the medical and scientific literature and/or the preclinical, nonclinical, animal, human, observational and/or other studies referred to above with respect to whether BYETTA or any other GLP-1 agonist or DPP-4 inhibitor CAUSES and/or is capable of CAUSING pancreatitis and/or pancreatic cancer.

RESPONSE:

This request is duplicative of Request Nos. 45 and 46 above, and Lilly refers Plaintiffs to its objections and response to those requests, which are incorporated as if set forth fully here.

REQUEST NO. 53:

All communications YOU have had with the author(s) of the medical and/or scientific literature referenced above with respect to whether BYETTA or any other GLP-1 agonist or DPP-4 inhibitor CAUSES and/or is capable of CAUSING pancreatic cancer.

RESPONSE:

This request is duplicative of Request Nos. 45 and 46 above, and Lilly refers Plaintiffs to its objections and response to those requests, which are incorporated as if set forth fully here. Lilly also objects to this request as ambiguous in that it does not define what is meant by "the medical and/or scientific literature referenced above." Lilly further objects to this request for "all" communications with unnamed authors as overbroad, unduly burdensome and not reasonably calculated to lead to discovery of competent evidence regarding general causation. The relevance of evidence to general causation does not depend on who it was communicated with.

REQUEST NO. 54:

All emails, letters, reports, memoranda and other written communications YOU have had internally regarding whether BYETTA or any other GLP-1 agonist or DPP-4 inhibitor CAUSES and/or is capable of CAUSING pancreatic cancer.

RESPONSE:

This request is duplicative of Request Nos. 45 and 46 above, and Lilly refers Plaintiffs to its objections and response to those requests, which are incorporated as if set forth fully here.

REQUEST NO. 55:

If YOU have made and/or requested label changes in the United States or elsewhere to add or strengthen warnings about the risks of pancreatitis and/or pancreatic cancer associated with BYETTA at any time since YOU began to market BYETTA, provide all DOCUMENTS, including emails, letters, reports, memoranda and other written communications, that YOU have sent to or received from the FDA and/or any applicable foreign country's regulatory authority in connection with each label change and/or request. This request to produce includes, without limitation, any PAS or CBE submitted by YOU to the FDA, and any response YOU have received from the FDA.

RESPONSE:

Lilly has not made or requested label changes "to add or strengthen warnings" regarding the alleged risk of pancreatic cancer. Lilly objects to this request as not relevant to general causation of pancreatic cancer to the extent it seeks documents regarding labeling for pancreatitis. Lilly also objects to discovery of foreign labeling as not relevant to this litigation, which involves Byetta labeling and use in the United States.

REQUEST NO. 56:

All emails, letters, reports, memoranda and other written communications to or from any source discussing or referring to physician monitoring and/or testing for pancreatitis and/or pancreatic cancer associated with the use of BYETTA.

RESPONSE:

Lilly objects to this request as unintelligible. To the extent the request seeks communications with "any source," it is also not reasonably calculated to discovery of evidence competent to prove or disprove general causation.

REQUEST NO. 57:

The meeting minutes and any summaries of meeting minutes for each internal meeting at which YOU discussed whether BYETTA or any other GLP-1 agonist DPP-4 inhibitor CAUSES and/or is capable of CAUSING pancreatitis and/or pancreatic cancer.

RESPONSE:

This request is duplicative of Request No. 46 above, and Lilly refers Plaintiffs to its objections and response to that request, which are incorporated as if set forth fully here. Lilly further objects to this request as overbroad, unduly burdensome, and not reasonably calculated to lead to discovery of competent evidence regarding general causation. As drafted, this request encompasses every document reflecting opinions by any individuals regardless of their expertise or knowledge. Lilly also objects to this interrogatory as overbroad to the extent it seeks information regarding pancreatitis.

REQUEST NO. 58:

All notes, recordings, handouts, materials and presentations YOU or YOUR employees are aware of that were made or obtained in connection with any meeting, conference or other event, internal or external, at which the subject of whether BYETTA or any other GLP-1 agonist or DPP-4 inhibitor CAUSES and/or is capable of CAUSING pancreatitis and/or pancreatic cancer was discussed.

RESPONSE:

This request is duplicative of Request No. 46 above, and Lilly refers Plaintiffs to its objections and response to that request, which are incorporated as if set forth fully here. Lilly further objects to this request as overbroad, unduly burdensome, and not reasonably calculated to lead to discovery of competent evidence regarding general causation. As drafted, this request encompasses every

document reflecting opinions by any individuals regardless of their expertise or knowledge.

REQUEST NO. 59:

If the sale of BYETTA has ever been prohibited due to concerns that it may CAUSE pancreatitis and/or pancreatic cancer, produce all emails, letters, reports, memoranda and other written communications received by YOU addressing or discussing those concerns, and all emails, letters, reports, memoranda and other written communications prepared by YOU (whether sent or not sent) addressing or discussing those concerns.

RESPONSE:

Not applicable. The sale of Byetta has not been prohibited since it was initially approved by the FDA as safe and effective.

REQUEST NO. 60:

If any of YOUR employees, officers, directors, agents, contractors, key opinion leaders, members of speakers' bureaus, advisory board members, or scientific advisors have corresponded with or supplied information or data to any scientific journal regarding whether BYETTA or any other GLP-1 agonist or DPP-4 inhibitor CAUSES and/or is capable of CAUSING pancreatitis and/or pancreatic cancer, produce the correspondence, information and/or data.

RESPONSE:

Lilly objects to this request as ambiguous, overbroad, and not reasonably calculated to lead to discovery of evidence relevant to prove or disprove general causation. The relevance or competence of evidence to prove or disprove general causation is not dependent on whom it was communicated to. To the extent this request seeks evidence that is relevant to prove or disprove general causation, it is duplicative of Plaintiffs' other requests that seek such evidence more directly.

Lilly also objects to this request as overbroad, unduly burdensome, and not reasonably calculated to lead to admissible evidence in that it seeks documents related to products other than Byetta, which is the only product at issue in Plaintiffs' claims against Lilly. Discovery directed to Lilly regarding other compounds in the GLP-1 or DPP-4 classes is overbroad, unduly burdensome, and not reasonably calculated to lead to admissible evidence. Lilly also objects to this interrogatory as overbroad to the extent it seeks information regarding pancreatitis. Lilly further objects to this request as overbroad, unreasonably burdensome, and exceeding the scope of Rule 34 to the extent it seeks production from Lilly of communications by third parties such as "contractors, key opinion leaders, members of speakers' bureaus, advisory board members, or scientific advisors."

REQUEST NO. 61:

If any of YOUR employees, officers, directors, agents, contractors, key opinion leaders, members of speakers' bureaus, advisory board members, or scientific advisors have submitted a manuscript, case report, article described as an "advertisement," opinion piece or topic to any scientific journal regarding whether BYETTA or any other GLP-1 agonist or DPP-4 inhibitor CAUSES and/or is capable of CAUSING pancreatitis and/or pancreatic cancer, produce the material submitted.

RESPONSE:

Lilly objects to this request as ambiguous, overbroad, and not reasonably calculated to lead to discovery of evidence relevant to prove or disprove general causation. The relevance or competence of evidence to prove or disprove general causation is not dependent on whom it was communicated to. To the extent this request seeks evidence that is relevant to prove or disprove general causation, it is duplicative of Plaintiffs' other requests that seek such evidence more directly. Lilly also objects to this request as overbroad, unduly burdensome, and not

reasonably calculated to lead to admissible evidence in that it seeks documents related to products other than Byetta, which is the only product at issue in Plaintiffs' claims against Lilly. Discovery directed to Lilly regarding other compounds in the GLP-1 or DPP-4 classes is overbroad, unduly burdensome, and not reasonably calculated to lead to admissible evidence. Lilly also objects to this interrogatory as overbroad to the extent it seeks information regarding pancreatitis. Lilly further objects to this request as overbroad, unreasonably burdensome, and exceeding the scope of Rule 34 to the extent it seeks production from Lilly of communications by third parties such as "contractors, key opinion leaders, members of speakers' bureaus, advisory board members, or scientific advisors."

REQUEST NO. 62:

If any of YOUR employees, officers, directors, agents, contractors, key opinion leaders, members of speakers' bureaus, advisory board members, or scientific advisors have participated in or supplied information or data to any expert meeting, panel or committee investigating or reviewing whether BYETTA or any other GLP-1 agonist or DPP-4 inhibitor CAUSES and/or is capable of CAUSING pancreatitis and/or pancreatic cancer, produce the correspondence, data and other DOCUMENTS supplied to, received from, or created by such meeting(s), panel(s) or committee proceedings.

RESPONSE:

Lilly objects to this request as ambiguous, overbroad, and not reasonably calculated to lead to discovery of evidence relevant to prove or disprove general causation. The relevance or competence of evidence to prove or disprove general causation is not dependent on whom it was communicated to. To the extent this request seeks evidence that is relevant to prove or disprove general causation, it is duplicative of Plaintiffs' other requests that seek such evidence more directly. Lilly also objects to this request as overbroad, unduly burdensome, and not

reasonably calculated to lead to admissible evidence in that it seeks documents related to products other than Byetta, which is the only product at issue in Plaintiffs' claims against Lilly. Discovery directed to Lilly regarding other compounds in the GLP-1 or DPP-4 classes is overbroad, unduly burdensome, and not reasonably calculated to lead to admissible evidence. Lilly also objects to this interrogatory as overbroad to the extent it seeks information regarding pancreatitis. Lilly further objects to this request as overbroad, unreasonably burdensome, and exceeding the scope of Rule 34 to the extent it seeks production from Lilly of communications by third parties such as "contractors, key opinion leaders, members of speakers' bureaus, advisory board members, or scientific advisors."

REQUEST NO. 63:

If any of YOUR employees, officers, directors, agents, contractors, key opinion leaders, members of speakers' bureaus, advisory board members, or scientific advisors corresponded with or supplied information or data to any authors, medical journals, scientific journals, any other publications, any diabetes research or research-funding organizations or persons affiliated with them, any scientific advisors, or any consultants about Dr. Susan Bonner-Weir, Dr. Alexandra E. Butler, Dr. Peter C. Butler, Dr. David D. Dore, Dr. Daniel J. Drucker, Dr. Michael Elashoff, Dr. Robert Elashoff, Dr. Edwin Gale, Dr. Rajesh Garg, Dr. Belinda Gier, Dr. Fred Gorlick, Dr. Steven Kami, Dr. Jacqueline Koehler, Dr. Aleksey V. Matveyenko, Dr. Robert Ratner, Dr. Sonal Singh, or Dr. Jay S. Skyler, and/or about any of the work they have done or authored regarding incretin medications, produce the correspondence, information and/or data.

RESPONSE:

Lilly objects to this request as ambiguous, overbroad, and not reasonably calculated to lead to discovery of evidence relevant to prove or disprove general causation. The relevance or competence of evidence to prove or disprove

general causation is not dependent on whom it was communicated to. To the extent this request seeks evidence that is relevant to prove or disprove general causation, it is duplicative of Plaintiffs' other requests that seek such evidence more directly. Lilly also objects to this request as overbroad, unduly burdensome, and not reasonably calculated to lead to admissible evidence in that it seeks documents related to products other than Byetta, which is the only product at issue in Plaintiffs' claims against Lilly. Discovery directed to Lilly regarding other compounds in the GLP-1 or DPP-4 classes is overbroad, unduly burdensome, and not reasonably calculated to lead to admissible evidence. Lilly also objects to this interrogatory as overbroad to the extent it seeks information regarding pancreatitis. Lilly further objects to this request as overbroad, unreasonably burdensome, and exceeding the scope of Rule 34 to the extent it seeks production from Lilly of communications by third parties such as "contractors, key opinion leaders, members of speakers' bureaus, advisory board members, or scientific advisors."

REQUEST NO. 64:

To the extent not already produced in response to the preceding requests, all emails, letters, reports, memoranda and other written communications with authors, medical journals, scientific journals, any other publications, any diabetes research or research-funding organizations or persons affiliated with them, any scientific advisors, or any consultants about whether BYETTA or any other GLP-1 agonist or DPP-4 inhibitor CAUSES and/or is capable of CAUSING pancreatitis and/or pancreatic cancer.

RESPONSE:

Lilly objects to this request as ambiguous, overbroad, and not reasonably calculated to lead to discovery of evidence competent to prove or disprove general causation. The relevance or competence of evidence to prove or disprove general causation is not dependent on whom it was communicated to. To

the extent this request seeks evidence that is relevant to prove or disprove general causation, it is duplicative of Plaintiffs' other requests that seek such evidence more directly. Lilly also objects to this request as overbroad, unduly burdensome, and not reasonably calculated to lead to admissible evidence in that it seeks documents related to products other than Byetta, which is the only product at issue in Plaintiffs' claims against Lilly. Discovery directed to Lilly regarding other compounds in the GLP-1 or DPP-4 classes is overbroad, unduly burdensome, and not reasonably calculated to lead to admissible evidence. Lilly also objects to this interrogatory as overbroad to the extent it seeks information regarding pancreatitis. Lilly further objects to this request as overbroad, unreasonably burdensome, and exceeding the scope of Rule 34 to the extent it seeks production from Lilly of communications by third parties such as "contractors, key opinion leaders, members of speakers' bureaus, advisory board members, or scientific advisors."

REQUEST NO. 65:

All DOCUMENTS that constitute or discuss compensation, honoraria, grants, scholarships or gifts, whether offered or actually paid, to individuals or institutions for work (including, without limitation, work done on preclinical studies, nonclinical studies, animal studies, human studies, other research, or the authorship of articles) concerning whether BYETTA or any other GLP-1 agonist or DPP-4 inhibitor CAUSES and/or is capable of CAUSING pancreatitis and/or pancreatic cancer. Include in YOUR response, without limitation, all such DOCUMENTS pertaining to Dr. Susan Bonner-Weir, Dr. David D. Dore, Dr. Daniel J. Drucker, Dr. Rajesh Garg, Dr. Fred Gorlick, Dr. Steven Kahn, Dr. Jacqueline Koehler, Dr. Robert Ratner, Dr. Jay S. Skyler, and/or the companies and/or organizations that employ them.

RESPONSE:

Lilly objects to this request as ambiguous, overbroad, and not reasonably calculated to lead to discovery of evidence competent to prove or disprove general causation. The financial information sought by this request has no tendency to prove or disprove the scientific fact of whether Byetta is capable of causing pancreatic cancer. Lilly also objects to this request as overbroad, unduly burdensome, and not reasonably calculated to lead to admissible evidence in that it seeks documents related to products other than Byetta, which is the only product at issue in Plaintiffs' claims against Lilly. Discovery directed to Lilly regarding other compounds in the GLP-1 or DPP-4 classes is overbroad, unduly burdensome, and not reasonably calculated to lead to admissible evidence. Lilly also objects to this interrogatory as overbroad to the extent it seeks information regarding pancreatitis. Lilly further objects to this request as overbroad, unreasonably burdensome, and exceeding the scope of Rule 34 to the extent it seeks production from Lilly of communications by third parties such as "contractors, key opinion leaders, members of speakers' bureaus, advisory board members, or scientific advisors."

REQUEST NO. 66:

All of YOUR DOCUMENT retention, destruction and archiving policies that apply to BYETTA preclinical, nonclinical, animal, human and/or observational studies; other studies addressing, in whole or in part, whether BYETTA CAUSES and/or is capable of CAUSING pancreatitis and/or pancreatic cancer; BYETTA ADVERSE EVENTS; and any other DOCUMENTS addressing whether BYETTA CAUSES and/or is capable of CAUSING pancreatitis and/or pancreatic cancer.

RESPONSE:

Lilly objects to this request as overbroad and not reasonably calculated to lead to discovery of evidence competent to prove or disprove general causation.

Record retention policies are unrelated to the issue of general causation. Lilly also objects to this request to the extent it includes material protected by the attorney-client privilege and/or attorney work product doctrine.

REQUEST NO. 67:

To the extent that YOU have withheld any DOCUMENTS responsive to any of these requests under any claim of privilege, produce a privilege log as required by Fed. R. Civ. P. 26.

RESPONSE:

Lilly has provided privilege logs for the productions it has made to date and will provide privilege logs for future productions, as well. However, Lilly notes that Plaintiffs' failure to respond to Defendants' proposed stipulation regarding the form and content of privilege logs is delaying Defendants' ability to begin preparation of privilege logs for productions that are currently in progress.

DATED: May 9, 2014

PEPPER HAMILTON LLP



By: _____
Nina M. Gussack
Kenneth J. King
Allan A. Thoen
Attorneys for Defendant
Eli Lilly and Company

DECLARATION OF SERVICE

I am over the age of eighteen years and not a party to the within action. I am a resident of or employed in the county where the service described below occurred. My business address is 3000 Two Logan Square, Philadelphia, PA 19103. I am familiar with this firm's practice for collection and processing of correspondence for mailing with the United States Postal service. In the ordinary course of business, correspondence collected from me would be processed on the same day, with postage thereon fully prepaid and placed for deposit that day with the United States Postal Service.

On May 9, 2014 I served the following:

> Defendant Eli Lilly and Company's Objections and Responses to Plaintiffs' General Causation Requests to Produce

by putting a true and correct copy thereof in a sealed envelope, with postage fully prepaid, and placing the envelope for collection and mailing today with the United States Postal Service in accordance with the firm's ordinary business practice, and/or by electronic mail, addressed as follows:

Michael K. Johnson
Johnson Becker, PLLC
33 South Sixth Street, Suite 4530
Minneapolis, MN 55402
mjohnson@JohnsonBecker.com
Served by Email

Ryan L. Thompson
Watts Guerra LLP
5250 Prue Road, Suite 525
San Antonio, TX 78240
rthompson@wattsguerra.com
Served by Email

Hunter J. Shkolnik
Napoli, Bern, Ripka
& Shkolnik LLP
350 Fifth Avenue
New York, NY 10018
Hunter@NapoliBern.com
Served by Email

Tor A. Hoerman
Torhoerman Law LLC
101 W. Vandalia Street, Suite 350
Edwardsville, IL 62025
thoerman@torhoermanlaw.com
Served by Email

I hereby certify that a copy of the above and foregoing has been mailed and/or sent by electronic mail to the following counsel of record for all of the actions that will be affected on May 9, 2014.

Allan A. Thoen
Attorney for Defendant
Eli Lilly and Company